Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab and Trastuzumab in Metastatic HER2-Positive Breast Cancer
NCT04307329Phase 2Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2021
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of monalizumab in HER2-positive metastatic breast cancer, sponsored by Netherlands Cancer Institute. Started Mar 2021; status: completed.
02
Drugs
monalizumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT04307329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04307329.